Abstract
Multiple markers are used in the prognostication of CLL, most important being the immunoglobulin hyper-variable region (IGHV) mutational status and cytogenetics. However, there may be predictive value for some new agents (venetoclax) as well as chemo-immunotherapy regimens in the presence or
absence of bulky lymphadenopathy (Roberts, 2019). There is no clear definition for “bulky disease”in the literature. Some groups define it as the presence of any lymph node 350 mm as determined by radiological scans or clinical examination. Although there has been documented association between bulky disease and del(11q), this is not a consistent finding (Dohner. Blood. 1997; Joshi. Can Gen. 2007; Jain. Blood. 2012). The purpose of this study was to assess the impact of bulky disease on patient outcome and to reassess cytogenetic and other relationships.
absence of bulky lymphadenopathy (Roberts, 2019). There is no clear definition for “bulky disease”in the literature. Some groups define it as the presence of any lymph node 350 mm as determined by radiological scans or clinical examination. Although there has been documented association between bulky disease and del(11q), this is not a consistent finding (Dohner. Blood. 1997; Joshi. Can Gen. 2007; Jain. Blood. 2012). The purpose of this study was to assess the impact of bulky disease on patient outcome and to reassess cytogenetic and other relationships.
Original language | English |
---|---|
Pages (from-to) | 207-209 |
Number of pages | 3 |
Journal | Leukemia and Lymphoma |
Volume | 61 |
Issue number | S1 |
DOIs | |
Publication status | Published - 21 May 2020 |
Event | XVIII International Workshop on Chronic Lymphocytic Leukemia - EICC: Edinburgh International Conference Centre, Edinburgh, United Kingdom Duration: 20 Sept 2019 → 23 Sept 2019 https://www.iwcll2019.org/ (Conference website) |
Keywords
- bulky lymphomatous disease
- non-bulky lymphomatous disease
- chronic lymphocytic leukaemia
- prognostication
- IGHV
- mutational status
- Cytogenetics
- venetoclax
- chemo-immunotherapy